Literature DB >> 22744336

Targeting the intrinsic inflammatory pathway: honokiol exerts proapoptotic effects through STAT3 inhibition in transformed Barrett's cells.

Chunhua Yu1, Qiuyang Zhang, Hui Ying Zhang, Xi Zhang, Xiaofang Huo, Edaire Cheng, David H Wang, Jack L Arbiser, Stuart Jon Spechler, Rhonda F Souza.   

Abstract

One way to link chronic inflammation with cancer is through the intrinsic inflammatory pathway, in which genetic alterations that induce malignant transformation also produce a cancer-promoting, inflammatory microenvironment. Signal transducer and activator of transcription 3 (STAT3) contributes to the intrinsic inflammatory pathway in Barrett's esophagus. In human tumors, honokiol (a polyphenol in herbal teas) has growth-inhibitory and proapoptotic effects associated with suppressed activation of STAT3. We used human Barrett's epithelial and esophageal adenocarcinoma cell lines to determine effects of honokiol on cell number, necrosis, apoptosis, and anchorage-independent growth and to explore STAT3's role in those effects. We determined Ras activity and expression of phosphorylated ERK1/2, phosphorylated Akt, and phosphorylated STAT3 in the presence or absence of honokiol. Cells were infected with constitutively active Stat3-C to assess effects of honokiol-induced STAT3 inhibition on apoptosis. Honokiol decreased cell number and increased necrosis and apoptosis in transformed Barrett's cells, but not in nontransformed cells. In adenocarcinoma cells, honokiol also increased necrosis and apoptosis and decreased anchorage-independent growth. Within 30 min of honokiol treatment, transformed Barrett's cells decreased expression of phosphorylated STAT3; decreases in Ras activity and phosphorylated ERK1/2 expression were detected at 24 h. Infection with Stat3-C significantly reduced apoptosis after honokiol treatment. Honokiol causes necrosis and apoptosis in transformed Barrett's and esophageal adenocarcinoma cells, but not in nontransformed Barrett's cells, and the proapoptotic effects of honokiol are mediated by its inhibition of STAT3 signaling. These findings suggest a potential role for targeting the intrinsic inflammatory pathways as a therapeutic strategy to prevent Barrett's carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22744336      PMCID: PMC3468554          DOI: 10.1152/ajpgi.00033.2012

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  27 in total

1.  Immortalization and transformation of primary human airway epithelial cells by gene transfer.

Authors:  Ante S Lundberg; Scott H Randell; Sheila A Stewart; Brian Elenbaas; Kimberly A Hartwell; Mary W Brooks; Mark D Fleming; John C Olsen; Scott W Miller; Robert A Weinberg; William C Hahn
Journal:  Oncogene       Date:  2002-07-04       Impact factor: 9.867

2.  Stat3 as an oncogene.

Authors:  J F Bromberg; M H Wrzeszczynska; G Devgan; Y Zhao; R G Pestell; C Albanese; J E Darnell
Journal:  Cell       Date:  1999-08-06       Impact factor: 41.582

3.  Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.

Authors:  A Herskovic; K Martz; M al-Sarraf; L Leichman; J Brindle; V Vaitkevicius; J Cooper; R Byhardt; L Davis; B Emami
Journal:  N Engl J Med       Date:  1992-06-11       Impact factor: 91.245

Review 4.  Concepts in the prevention of adenocarcinoma of the distal esophagus and proximal stomach.

Authors:  Rhonda F Souza; Stuart J Spechler
Journal:  CA Cancer J Clin       Date:  2005 Nov-Dec       Impact factor: 508.702

5.  Honokiol: a potent chemotherapy candidate for human colorectal carcinoma.

Authors:  Fei Chen; Tao Wang; Yi-Feng Wu; Ying Gu; Xiao-Li Xu; Shu Zheng; Xun Hu
Journal:  World J Gastroenterol       Date:  2004-12-01       Impact factor: 5.742

6.  Activation of c-Ki-ras in human gastrointestinal dysplasias determined by direct sequencing of polymerase chain reaction products.

Authors:  S J Meltzer; S M Mane; P K Wood; J H Resau; C Newkirk; J A Terzakis; B I Korelitz; W M Weinstein; S W Needleman
Journal:  Cancer Res       Date:  1990-06-15       Impact factor: 12.701

7.  The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma.

Authors:  Carlo C Maley; Patricia C Galipeau; Xiaohong Li; Carissa A Sanchez; Thomas G Paulson; Patricia L Blount; Brian J Reid
Journal:  Cancer Res       Date:  2004-10-15       Impact factor: 12.701

8.  Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus.

Authors:  B Klump; C J Hsieh; K Holzmann; M Gregor; R Porschen
Journal:  Gastroenterology       Date:  1998-12       Impact factor: 22.682

9.  Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma.

Authors:  Florian Sommerer; Michael Vieth; Annett Markwarth; Knut Röhrich; Susanne Vomschloss; Andrea May; Christian Ell; Manfred Stolte; Ulrich R Hengge; Christian Wittekind; Andrea Tannapfel
Journal:  Oncogene       Date:  2004-01-15       Impact factor: 9.867

10.  Differential expression of c-myc and H-ras oncogenes in Barrett's epithelium. A study using colorimetric in situ hybridization.

Authors:  O M Abdelatif; F W Chandler; L R Mills; B S McGuire; C G Pantazis; J M Barrett
Journal:  Arch Pathol Lab Med       Date:  1991-09       Impact factor: 5.534

View more
  11 in total

1.  Endogenous transmembrane protein UT2 inhibits pSTAT3 and suppresses hematological malignancy.

Authors:  Dongjun Lee; Ying-Hua Wang; Demetrios Kalaitzidis; Janani Ramachandran; Homare Eda; David B Sykes; Noopur Raje; David T Scadden
Journal:  J Clin Invest       Date:  2016-02-29       Impact factor: 14.808

2.  Honokiol inhibits androgen receptor activity in prostate cancer cells.

Authors:  Eun-Ryeong Hahm; A Isabella Karlsson; Michael Y Bonner; Jack L Arbiser; Shivendra V Singh
Journal:  Prostate       Date:  2013-12-11       Impact factor: 4.104

3.  Diet-related inflammation and oesophageal cancer by histological type: a nationwide case-control study in Sweden.

Authors:  Yunxia Lu; Nitin Shivappa; Yulan Lin; Jesper Lagergren; James R Hébert
Journal:  Eur J Nutr       Date:  2015-07-19       Impact factor: 5.614

4.  Honokiol and Magnolol Inhibit CXCL10 and CXCL11 Production in IL-27-Stimulated Human Oral Epithelial Cells.

Authors:  Yoshitaka Hosokawa; Ikuko Hosokawa; Kazumi Ozaki; Takashi Matsuo
Journal:  Inflammation       Date:  2018-12       Impact factor: 4.092

5.  The natural product honokiol inhibits calcineurin inhibitor-induced and Ras-mediated tumor promoting pathways.

Authors:  Pallavi Banerjee; Aninda Basu; Jack L Arbiser; Soumitro Pal
Journal:  Cancer Lett       Date:  2013-06-07       Impact factor: 8.679

6.  Honokiol as a Radiosensitizing Agent for Colorectal cancers.

Authors:  Zhiyun He; Dharmalingam Subramaniam; Zhongtao Zhang; Youcheng Zhang; Shrikant Anant
Journal:  Curr Colorectal Cancer Rep       Date:  2013-12

7.  Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial Sirt3.

Authors:  Vinodkumar B Pillai; Sadhana Samant; Nagalingam R Sundaresan; Hariharasundaram Raghuraman; Gene Kim; Michael Y Bonner; Jack L Arbiser; Douglas I Walker; Dean P Jones; David Gius; Mahesh P Gupta
Journal:  Nat Commun       Date:  2015-04-14       Impact factor: 14.919

8.  Inducing apoptosis of cancer cells using small-molecule plant compounds that bind to GRP78.

Authors:  S Martin; H K Lamb; C Brady; B Lefkove; M Y Bonner; P Thompson; P E Lovat; J L Arbiser; A R Hawkins; C P F Redfern
Journal:  Br J Cancer       Date:  2013-06-27       Impact factor: 7.640

Review 9.  The tumor microenvironment in esophageal cancer.

Authors:  E W Lin; T A Karakasheva; P D Hicks; A J Bass; A K Rustgi
Journal:  Oncogene       Date:  2016-02-29       Impact factor: 9.867

Review 10.  Honokiol: A Review of Its Anticancer Potential and Mechanisms.

Authors:  Chon Phin Ong; Wai Leong Lee; Yin Quan Tang; Wei Hsum Yap
Journal:  Cancers (Basel)       Date:  2019-12-22       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.